Advert - Napp

For making unacceptable payments to health professionals to attend a meeting that promoted Remsima (infliximab), and thus was not a genuine advisory board, Napp was ruled in breach of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry.

Clause 9.1 - Failing to maintain high standards.

Clause 12.1 - Disguised promotion.

Clause 18.1 - Paying health professionals to attend a promotional meeting.

Clause 23.1 - Engaging health professionals in other than genuine consultancy arrangements.

The full case report was published in the PMCPA August Code of Practice Review and is available at